Skip to main content
. Author manuscript; available in PMC: 2020 Sep 7.
Published in final edited form as: Nanoscale. 2019 Aug 13;11(33):15647–15658. doi: 10.1039/c9nr04828f

Figure 4. In vivo characterization of NBs in mouse kidney stability relative to commercially available UCA in mice.

Figure 4.

(a) NBs and commercially available UCA (Lumason) were injected via tail-vein and a cross-section of the kidney and liver was imaged at 12 MHz, 245 kPa pressure, and 0.2 frames per second. Left: Representative B-mode images of the kidney and liver before the injection of UCAs. 0 min-20 mins: Series of images showing the signal onset and signal decay of various UCAs at different time points. Minimal to no contrast can be observed before injection (t= 0) which is expected because backscatter signals from kidney and liver do not have any nonlinear properties. (b) Representative signal decay curve of NBs and Lumason® showing the delayed signal decay onset and longer in vivo half-life of PG-Gly-PL. (c) In vivo maximum enhancement, (d) in vivo washout half-life, and (e) in vivo decay onset of NBs and Lumason extracted from the enhancement vs time curve.